References
- Bissery M C, Nohynek G, Sandernink G J. Docetaxel: a review of preclinical and clinical experience. Part I. Clinical experience. Anti-Cancer Drugs 1943–1951; 6, 1995
- Haldar S, Chintapalli J, Croce C. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253–1255
- Belotti D, Vergani V, Drudis T. The microtubule drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843–1849
- Stracke M L, Soroush M, Liotta L A. Cytoskelatal agents inhibit motility and adherence of human tumor cells. Kidney Int 1993; 43: 151–157
- Verschueren H, Dewit J, DeBrackeller J. Motility and invasive potency of murine T-lymphoma cells: effect of microtubules inhibitors. Cell Biol Int 1994; 128: 11–19
- Knick V C, Eberwein D J, Miller C G. Preclinical activity of Navelbine and Taxol drug combinations. Proc Am Assoc Cancer Res 1994; 35A: 327, abstract 1945
- Adams D J. Synergy of Navelbine, Taxol combination treatment in two human breast cancer cell lines. Proc Am Assoc Cancer Res 1994; 35A: 327, abstract 1944
- Photiou A, Shah P, Leong L K. In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines. Eur J Cancer 1997; 33: 463–470
- Romero Acuna L, Langhi M, Perez J. Vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy (FLC) in metastatic breast cancer (MBC): final results. Proc Am Soc Clin Oncol 1998; 17: 171a, abstract 633
- Martin M, Garcia Carbonero I, Lluch A. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Proc Am Soc Clin Oncol 1998; 17: 158a, abstract 604
- Gardin G, Pronzato P, Tognoni A. A phase II trial of vinorelbine (v) and paclitaxel (p) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline containing chemotherapy. Proc Am Soc Clin Oncol 1998; 17: 142a, abstract 542
- Monnier A, Riviere A, Douillard J Y. Phase II study of docetaxel (Taxotere) and vinorelbine in chemotherapy naive patients with advanced non small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 1996; 15: 378, abstract 1129
- Kourousis C, Kakolyris S, Androullakis N. First line treatment on non-small cell lung carcinoma with docetaxel and vinorelbine: a phase II study. Proc Am Soc Clin Oncol 1996; 15: 405, abstract 1234
- Viallet J, Laberge F, Martins H. Docetaxel alternating with cisplatin and vinorelbine: early evidence of additive activity in a phase II trial of non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1996; 15: 375, abstract 1115
- Sledge GW, Jr, Neuberg D, Ingle J. Phase III trial of doxorubicin versus paclitaxel versus doxorubicin plus paclitaxel as firstline therapy for metastatic breast cancer: an Intergroup trial. Proc Am Soc Clin Oncol 1997; 16: la, abstract 2
- Slamon D, Leyland-Jones B, Shak S. Addition of HerceptinTM (humanized anti-her2 antibody) to first line chemotherapy for her2 overexpressing metastatic breast cancer markedly increased anticancer activity: a randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998; 17: 98a, abstract 377
- Bums H. Personal communication 1999
- Nabholtz J M, Falkson G, Campos D. A phase HI trial comparing doxorubicin and docetaxel to doxorubicin and cyclophos phamide as first line therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 127a, abstract 485
- Seidman A D, Hudis C A, Albanel J. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 3353–3361
- Perez E A, Irwin D H, Patel R. A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 126a, abstract 480
- Burstein J H, Younger J, Bunnell C A. Weekly docetaxel (Taxotere®) for metastatic breast cancer: a phase II trial. Proc Am Soc Clin Oncol 1999; 18: 127a, abstract 484
- Baselga J, Norton L, Albanell J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing, human breast cancer xenografts. Cancer Res 1998; 58: 2825–2831
- Fornier M, Seidman A D, Esteva F J. Weakly Herceptin plus 1 hour Taxol: phase II study in HER2 overexpressing and non-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 126a, abstract 482
- Henderson I C, Berry D, Demetri G. Improved disease free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive breast cancer. Proc Am Soc Clin Oncol 1998; 17: 101a, abstract 390a